zinc finger protein 236Genealiases: ZNF236A · ZNF236B
Q-omics provides the consensus-scored ZNF236 profile across patient tissues and cancer cell-line models. ZNF236 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ZNF236 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, ZNF236 RNA expression shows 21,722 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, THCA, and UVM as cancer lineages where ZNF236 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF236 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF236 survival associations across molecular data types. ZNF236 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF236 RNA expression–survival associations across cancer types. High ZNF236 expression shows unfavorable associations in ACC, BLCA, MESO and UVM, but favorable associations in BRCA and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ZNF236 RNA expression.
This table summarizes ZNF236 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF236. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF236 shows lower tumor expression in THCA and higher tumor expression in LIHC, CHOL, HNSC, LUSC and STAD. The THCA box plot shows higher ZNF236 RNA expression in normal versus tumor tissue (log2 FC = −0.588, t-test p < 0.001).
This table shows molecular features associated with ZNF236 in patient tissues and cancer cell lines. In patient samples, ZNF236 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF236 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
